For more than 20 years, through clinical trials, registries and site-reported use, the GORE® TAG® Device family has proven to be safe, effective and durable, earning the trust of physicians worldwide.
Type III endoleaks†
TYPE B DISSECTION
migration shown in
See latest results
* GORE® TAG® Conformable Device.
† Endoleak requiring intervention. No endoleaks persisted past one month or required intervention.
- The GREAT Registry is a prospective, observational, multi-center registry to actively track Gore commercial aortic endovascular device performance and associated patient outcomes in global markets with 10 years of follow-up. Data June 2017. Through 2-year follow up. Aneurysm n=316; Transection n=53; Type B dissection n=269.
- Rates are based on physician experience as reported for 127 subjects in Europe within a 30-day follow-up period. European-Post Approval Registry: Observational Registry Characterizing the Performance and Feature Use of the GORE® TAG® Conformable Thoracic Stent Graft Featuring ACTIVE CONTROL System. (data on file 2017; W. L. Gore & Associates, Inc; Flagstaff, AZ.)
- Reported outcomes following 5-year-follow-up in FDA IDE clinical studies.